Category Archives: Novartis Case

Indian Pharmaceutical Alliance slams US over charges on Indian patent law

Source: Economic Times NEW DELHI: Indian Pharmaceutical Alliance (IPA) has contested US allegations that India’s patent Act is discriminatory and said America can go to WTO’s dispute settlement mechanism if such is the case. An industry body comprising mainly domestic … Continue reading

Posted in access to medicines, Drug Pricing, IP Rights, IPR Enforcement, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TRIPS, WTO | Tagged , , | Leave a comment

Engineered in India — Patent Law 2.0

Source: New England Journal of Medicine Amy Kapczynski, J.D. July 17 2013 India is known as the “pharmacy of the developing world,” because it supplies much of the world’s demand for affordable, generic drugs. So when the Supreme Court of … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, IP Rights, Novartis Case, patent, Right to Health, Sec 3 (d) | Leave a comment

A victory for access to medicines

Source:TWN The Indian Supreme Court’s 1 April decision which reaffirmed that only medicines that are genuinely new inventions should be granted patents has been hailed as a victory for the rights of patients to have affordable medicines.   Martin Khor PATIENTS … Continue reading

Posted in access to medicines, Generic drug, IP Rights, Novartis Case, patent, Sec 3 (d), TRIPS | Tagged | Leave a comment

The larger implications of the Novartis-Glivec judgment

Source: TWN Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. What the judgment says and what it implies … Continue reading

Posted in access to medicines, Generic drug, IP Rights, Novartis Case, patent, Sec 3 (d), TRIPS | Leave a comment

What should we learn from the Novartis judgment?

Source: TWN In the following piece, KM Gopakumar traces the legal background to the Indian Supreme Court decision on Novartis’ claim for a patent and explains the significance of some aspects of the judgment. ON 1 April the Supreme Court of India … Continue reading

Posted in access to medicines, Generic drug, IP Rights, Novartis Case, patent, Sec 3 (d) | Leave a comment

Intellectual property threats in the BRIC markets

Source: PMLive Compulsory licensing and other legal concerns for pharma in emerging markets For as long as pharma and biotech companies have contemplated doing business in BRIC, there have been questions about intellectual property (IP) risk.

Posted in access to medicines, BRICS, Compulsory Licensing, IP Rights, Novartis Case, patent | Tagged , , , , , , , | Leave a comment

40 Senators wrote to Secretary-US Government on India’s discriminatory trade practices

40 out of total hundred senators of US Government had written to John Kerry, Secretary, US Department of State stating their concerns about India’s discriminatory trade and economic practices. This letter was sent few days before John Kerry’s visit to … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, IP Rights, Novartis Case | Tagged , | Leave a comment